1. Home
  2. MASS vs CCAP Comparison

MASS vs CCAP Comparison

Compare MASS & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 908 Devices Inc.

MASS

908 Devices Inc.

SELL

Current Price

$12.85

Market Cap

498.1M

Sector

Health Care

ML Signal

SELL

Logo Crescent Capital BDC Inc.

CCAP

Crescent Capital BDC Inc.

HOLD

Current Price

$8.98

Market Cap

418.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MASS
CCAP
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
498.1M
418.9M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
MASS
CCAP
Price
$12.85
$8.98
Analyst Decision
Strong Buy
Hold
Analyst Count
6
7
Target Price
★ $13.38
$11.96
AVG Volume (30 Days)
★ 356.5K
222.4K
Earning Date
11-10-2026
11-11-2026
Dividend Yield
N/A
★ 16.29%
EPS Growth
★ 125.47
N/A
EPS
N/A
★ 0.42
Revenue
★ $56,197,000.00
N/A
Revenue This Year
$22.97
N/A
Revenue Next Year
$19.41
N/A
P/E Ratio
★ N/A
$21.21
Revenue Growth
N/A
★ N/A
52 Week Low
$5.03
$8.40
52 Week High
$13.35
$15.18

Technical Indicators

Market Signals
Indicator
MASS
CCAP
Relative Strength Index (RSI) 63.70 43.17
Support Level $6.06 $8.86
Resistance Level $13.35 $9.30
Average True Range (ATR) 0.58 0.20
MACD 0.01 0.05
Stochastic Oscillator 88.83 59.67

Price Performance

Historical Comparison
MASS
CCAP

About MASS 908 Devices Inc.

908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

About CCAP Crescent Capital BDC Inc.

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

Share on Social Networks: